Drug Type Chemical drugs |
Synonyms- |
Target |
Action inhibitors |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), Cholesterol absorption inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Primary hypercholesterolemia | Phase 3 | Australia | 01 Aug 2020 | |
| Primary hypercholesterolemia | Phase 3 | New Zealand | 01 Aug 2020 | |
| Primary hypercholesterolemia | Phase 3 | Taiwan Province | 01 Aug 2020 |
Phase 3 | 388 | 1PC111 (pitavastatin 2 mg and ezetimibe 10 mg) | hfqbxwpgyi(ofgnkbeioc) = qaetpxkhtw giximnqxwh (pbabonpsaq, 14.9%) | Positive | 24 Aug 2022 | ||
Pitavastatin 2 mg | hfqbxwpgyi(ofgnkbeioc) = cjoysodsov giximnqxwh (pbabonpsaq, 11.4%) |





